ProCE Banner Activity

My Thoughts on IO in HNSCC Today

Clinical Thought

In this commentary from a live webinar, Dr Barbara Burtness describes utilization of immunotherapies early during treatment for relapsed or metastatic head and neck cancers.

Released: September 12, 2023

Share

Faculty

Barbara Burtness

Barbara Burtness, MD

Anthony N. Brady Professor of Medicine
Yale School of Medicine
Chief Translational Research Officer
Division Chief
Head and Neck/Sarcoma Oncology
Co-leader
Developmental Therapeutics Program
Director
Yale Head and Neck SPORE
Yale Cancer Center
Chair
ECOG-ACRIN Cancer Research Group
New Haven, Connecticut

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Merck Sharp & Dohme, LLC

Merck Sharp & Dohme, LLC